Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > BUSINESS
BUSINESS
- Japan Vaccine Files NDA for Intradermal Influenza Vaccine
April 13, 2015
- Show Timelines for Vaccine Inclusion in Public Immunization Program: Pfizer Exec
April 10, 2015
- Ethical Drug Sales Down 1.4% in February: Crecon Report
April 10, 2015
- IFN-Free, All Oral Treatment for Hepatitis C Demonstrates Impressive Response Rate
April 10, 2015
- Livalo Shows No Negative Effects on Fasting Blood Glucose Levels, HbA1c: Kowa
April 10, 2015
- Regience Partners with Keio Univ. for Joint Research of Liver Regeneration
April 10, 2015
- Announcement: 8th Annual Marketing Excellence Japan 2015 - Westin Tokyo, May 12-13
April 9, 2015
- Novo Nordisk’s Japan Sales Bounce Back to Hit All-Time High
April 9, 2015
- Hisamitsu Sales Up 4.1% despite Dull Japan Biz, Mohrus Down 8.5%
April 9, 2015
- Eli Lilly Japan Sales Cross 200 Billion Yen in 2014, Top 10 Eyed by 2020
April 9, 2015
- Bayer Yakuhin Negotiating with Universities, Institutions for Research Agreements
April 9, 2015
- Merck KGaA, Pfizer to Copromote Xalkori in Japan, US, Europe
April 9, 2015
- Bayer Yakuhin Logs Double-Digit Growth for 2 Years Running on Xarelto
April 8, 2015
- BIKEN, Osaka University Strike License Agreement to Develop Novel Pneumococcal Vaccines
April 8, 2015
- Drug Makers Setting Up Medical Affairs Units Independent of Sales Teams
April 7, 2015
- Mochida Using “Granular Tablets” to Gain Share in Generic Drug Market
April 7, 2015
- Pfizer Japan Rolls Out Japan’s 1st Propecia Generic
April 7, 2015
- Biogen Idec Japan Names Steve Sugino, Former Sanofi Diabetes Head, as President
April 7, 2015
- Xtandi Significantly Prolongs PFS vs. Bicalutamide in US: Astellas
April 6, 2015
- Zelboraf a Promising New Treatment Option for Malignant Melanoma: Dr Yamazaki
April 6, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…